Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Induction of epitope-specific neutralizing antibodies against West Nile virus.

Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2007 Nov;81(21):11828-39. Epub 2007 Aug 22.

2.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

4.

A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.

5.

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.

6.

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS.

J Virol. 2011 Nov;85(22):11567-80. doi: 10.1128/JVI.05859-11. Epub 2011 Sep 14.

7.

Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step.

Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, Oliphant T, Nelson S, Pierson TC, Wilschut J, Throsby M, Diamond MS.

J Virol. 2009 Jul;83(13):6494-507. doi: 10.1128/JVI.00286-09. Epub 2009 Apr 22.

8.

Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Zlatkovic J, Stiasny K, Heinz FX.

J Virol. 2011 Mar;85(5):1994-2003. doi: 10.1128/JVI.01886-10. Epub 2010 Dec 8.

10.

Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.

Tinker JK, Yan J, Knippel RJ, Panayiotou P, Cornell KA.

Toxins (Basel). 2014 Apr 22;6(4):1397-418. doi: 10.3390/toxins6041397.

11.

Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay.

Namekar M, Kumar M, O'Connell M, Nerurkar VR.

PLoS One. 2012;7(9):e45851. doi: 10.1371/journal.pone.0045851. Epub 2012 Sep 25.

12.

The neutralizing antibody response against West Nile virus in naturally infected horses.

Sánchez MD, Pierson TC, Degrace MM, Mattei LM, Hanna SL, Del Piero F, Doms RW.

Virology. 2007 Mar 15;359(2):336-48. Epub 2006 Oct 20.

13.

Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM.

Virol J. 2010 May 12;7:95. doi: 10.1186/1743-422X-7-95.

14.

A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.

Liu SA, Haque M, Stanfield B, Andrews FM, Roy AA, Kousoulas KG.

Vet Microbiol. 2017 Jan;198:51-58. doi: 10.1016/j.vetmic.2016.12.008. Epub 2016 Dec 8.

PMID:
28062007
15.

The structural immunology of antibody protection against West Nile virus.

Diamond MS, Pierson TC, Fremont DH.

Immunol Rev. 2008 Oct;225:212-25. doi: 10.1111/j.1600-065X.2008.00676.x. Review.

16.

The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.

17.

A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17.

PMID:
21596075
18.

West Nile virus: characterization and diagnostic applications of monoclonal antibodies.

Lelli D, Moreno A, Brocchi E, Sozzi E, Capucci L, Canelli E, Barbieri I, Zeller H, Cordioli P.

Virol J. 2012 Apr 13;9:81. doi: 10.1186/1743-422X-9-81.

19.

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.

Chua AJ, Vituret C, Tan ML, Gonzalez G, Boulanger P, Ng ML, Hong SS.

Virol J. 2013 Apr 24;10:129. doi: 10.1186/1743-422X-10-129.

20.

A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, Haagmans BL, Provacia LB, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2011 Apr 26;6(4):e18995. doi: 10.1371/journal.pone.0018995.

Supplemental Content

Support Center